Explore

Clinicians Advocate for Human Oversight and Accountability in AI-Driven Clinical Decision Support

Clinicians Advocate for Human Oversight and Accountability in AI-Driven Clinical Decision Support

Clinicians are increasingly emphasizing the need for robust human oversight and clear accountability in AI-driven clinical decision support systems. Dr. Brandy Zachary, who built the LabDX software, highlights that while AI can efficiently compile patient data and draft care plans, the ultimate decision-making and interpretation must remain with the clinician. She argues that a 'human in the loop' is only effective if that person can conduct a meaningful review, questioning the AI's basis for recommendations and having the authority to override them. Concerns are rising about 'shadow AI' where clinicians use chatbots without formal IT approval, and studies have found errors and omissions in AI-generated summaries. Senator Bill Cassidy has circulated the PATIENT AI Act discussion draft to clarify regulatory oversight by the FDA and ONC, and to ensure review of software updates.

US District Court Partially Vacates CMS Rule on Medicaid Work Requirements, Broadening Medical Frailty Exemption

US District Court Partially Vacates CMS Rule on Medicaid Work Requirements, Broadening Medical Frailty Exemption

On October 29, 2026, the US District Court for the District of Massachusetts issued a ruling that partially vacated a portion of the Centers for Medicare & Medicaid Services (CMS) interim final rule regarding Medicaid work requirements. The court determined that CMS exceeded its authority by narrowing the interpretation of the medical-frailty exemption established by Congress. Specifically, the court found that Congress's five subcategories for medical frailty (including individuals who are blind, have substance use disorders, or disabling mental disorders) set a definitional floor, and CMS could not impose an additional functional-impairment requirement for individuals within these categories. For instance, CMS's rule would have required a blind individual to also prove a significant impairment to their ability to meet work requirements, which the court deemed beyond the agency's power. The court vacated the conflicting regulatory language and permanently enjoined its enforcement, though it upheld the rul...

Mayo Clinic Launches AI Chatbot for Internal Clinical Decision Support

Mayo Clinic Launches AI Chatbot for Internal Clinical Decision Support

Mayo Clinic is introducing a new AI-driven chatbot, the Clinical Decision Support (CDS) solution, for its doctors and healthcare providers. This chatbot is designed to assist clinicians by providing industry-standard medical information across more than 35 medical specialties and will have access to patients’ electronic health records. The goal is to streamline the process of finding relevant information for individualized patient care, allowing clinicians to dedicate more time to patient interaction rather than searching multiple resources. Maneesh Goyal, chief operating officer of Mayo Clinic Platform, stated that this solution integrates trusted Mayo Clinic knowledge directly into the clinical workflow. The Mayo Clinic emphasizes that doctors will retain full responsibility for all final medical decisions, with the AI serving as an assistive tool rather than a replacement for clinical judgment. The system will undergo continuous evaluation for safety, effectiveness, privacy, security, and clinical value...

Oscar Health Reports 70% Revenue Jump, Focuses on Workforce Shifts with Tailored Health Plans

Oscar Health Reports 70% Revenue Jump, Focuses on Workforce Shifts with Tailored Health Plans

Oscar Health Reports 70% Revenue Jump, Focuses on Workforce Shifts with Tailored Health Plans

CMS Finalizes Rule for Medicare Drug Price Negotiation Program, Strengthening Drug Cost Controls

CMS Finalizes Rule for Medicare Drug Price Negotiation Program, Strengthening Drug Cost Controls

On November 5, 2026, the Centers for Medicare & Medicaid Services (CMS) issued a final rule to codify policies for the Medicare Drug Price Negotiation Program, effective December 5, 2026. This rule establishes a permanent framework for negotiating prices of high-cost drugs, starting with prices applicable in 2029. The program aims to achieve greater value for beneficiaries and taxpayers while fostering innovation. The negotiation process involves engagement with primary manufacturers and interested parties, including patients, leading to an initial offer from CMS. Manufacturers can accept this offer or provide a counteroffer, followed by optional negotiation meetings and additional price exchange opportunities. The process concludes with a final offer from CMS. A significant new provision clarifies how CMS will identify qualifying single-source drugs, specifically addressing new formulations to prevent manufacturers from circumventing negotiation through minor product changes. This includes aggregating fix...

HHS Integrates VA and Defense Health into TEFCA Network to Unify Veteran and Service Member Care

HHS Integrates VA and Defense Health into TEFCA Network to Unify Veteran and Service Member Care

The U.S. Department of Health and Human Services (HHS), through its Office of the National Coordinator for Health Information Technology (ONC), has announced that the U.S. Department of Veterans Affairs (VA) and the Department of Defense (DoD) have officially joined the Trusted Exchange Framework and Common Agreement (TEFCA). This integration is a significant step in federal health IT policy, aiming to unify military, veteran, and civilian clinical data within a single national interoperability backbone. The expansion connects active-duty service members, veterans, and their families to America’s national health information exchange network. This move is designed to ensure that clinical data flows bidirectionally between private community providers, military treatment facilities (MTFs), and VA medical centers, addressing historical fragmentation in patient care continuity. The VA and DoD join other federal agencies already on TEFCA, including the Indian Health Service (IHS), the Consumer Product Safety Com...

Healthcare Sector Navigates AI Automation with Focus on Drudgery vs. Judgment Tasks

Healthcare Sector Navigates AI Automation with Focus on Drudgery vs. Judgment Tasks

The healthcare sector is strategically evaluating the implementation of AI automation by distinguishing between tasks that involve 'drudgery' and those requiring 'judgment.' A framework is being used to assess tasks based on how well AI performs them and the degree to which human judgment is necessary. Tasks where AI performs reliably and the manual work is repetitive and low-value, such as searching for values across documents or comparing data, are considered prime candidates for automation. This approach, exemplified by MRO's Prodigy™ for clinical data abstraction, aims to free healthcare professionals from tedious tasks, allowing them to focus on areas that genuinely require their expertise and critical thinking. Conversely, tasks where AI performs well but still necessitate human interpretation or decision-making, or where AI is not yet reliable, are kept under human oversight. The goal is not to eliminate human roles but to redefine them, shifting the focus from manual hunting to applying specialized...

HBox Seeks Care Coach with AI Interest for Chronic Condition Management

HBox Seeks Care Coach with AI Interest for Chronic Condition Management

HBox, a company focused on revolutionizing healthcare delivery through AI and innovative care solutions, is seeking a Care Coach (Virtual Medical Assistant). This role involves providing empathetic and patient-centered care to individuals with chronic conditions, supporting their care plans, and coaching them on healthy lifestyle choices. Key responsibilities include educating patients on diet, exercise, and medication adherence, offering personalized coaching to achieve health goals, and encouraging the use of vital monitoring tools. The ideal candidate will have a strong interest in the integration of AI technology in healthcare and its potential to enhance care delivery. Proficiency in various Electronic Medical Records (EMR) systems is essential, and bilingual proficiency in Arabic or Spanish is preferred.

Midterm Elections Reveal Negative Public Sentiment Towards AI, Potentially Shaping Health AI Legislation

Midterm Elections Reveal Negative Public Sentiment Towards AI, Potentially Shaping Health AI Legislation

The recent U.S. midterm elections highlighted a negative public sentiment towards artificial intelligence, with voters rejecting data centers—essential for powering AI—on numerous ballot measures across several states. These results align with polling data indicating that many Americans believe AI causes more harm than good. This widespread public attitude raises questions about how it will influence future legislation and policy regarding AI use in health care. Key issues for lawmakers next year include state bills proposing 'sandboxes' for testing AI products and national legislation aimed at clarifying the Food and Drug Administration's (FDA) authority over AI, as well as reimbursement policies for AI-driven health technologies.

HHS Secretary Robert F. Kennedy Jr. Issues Interim Policy on Compounding Six Peptides

HHS Secretary Robert F. Kennedy Jr. Issues Interim Policy on Compounding Six Peptides

On October 28, 2026, the U.S. Department of Health and Human Services (HHS) published an interim Enforcement Discretion Policy regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Signed by HHS Secretary Robert F. Kennedy Jr., this policy outlines conditions under which HHS will not take enforcement action against state-licensed pharmacies, federal facilities, and licensed physicians who compound drug products using six specific peptide bulk drug substances. This interim measure is in effect while the official list of bulk drug substances for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) is being developed through rulemaking. The policy aims to discourage the use of 'research use only' peptides from foreign manufacturers, offering a more controlled alternative for U.S. patients. Notably, this policy was issued by the HHS Office of the Secretary, rather than the FDA, despite FDA scientific reviewers having previously recommended against listing these pep...

Cohere Health's AI Pre-Payment Review Saves Medicare Advantage Client Over $10 Million

Cohere Health's AI Pre-Payment Review Saves Medicare Advantage Client Over $10 Million

Cohere Health's AI Pre-Payment Review Saves Medicare Advantage Client Over $10 Million

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges